To understand gene expression changes mediated by a polyglutamine repeat expansion in the human huntingtin protein, we used oligonucleotide DNA arrays to profile~6000 striatal mRNAs in the R6/2 mouse, a transgenic Huntington's disease (HD) model. We found diminished levels of mRNAs encoding components of the neurotransmitter, calcium and retinoid signaling pathways at both early and late symptomatic time points (6 and 12 weeks of age). We observed similar changes in gene expression in another HD mouse model (N171-82Q). These results demonstrate that mutant huntingtin directly or indirectly reduces the expression of a distinct set of genes involved in signaling pathways known to be critical to striatal neuron function.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder manifested by psychiatric, cognitive and motor symptoms typically starting in mid life and progressing relentlessly to death. HD is caused by an expansion of a polyglutamine-encoding region in exon 1 of the IT15 gene that encodes huntingtin (1) . Although huntingtin is ubiquitously expressed, the medium spiny GABAergic cells of the striatum are preferentially damaged in HD. There is no cure for this disorder and there is currently no therapeutic approach to delay the onset of symptoms.
Positron emission tomography (PET) studies of presymptomatic human patients indicate that neurotransmitter receptor decreases occur prior to the onset of overt clinical symptoms (2) . We have recently demonstrated decreases in neurotransmitter receptors in a transgenic mouse HD model which are selective in that certain receptors are decreased while others are not (3, 4) . The pattern of neurotransmitter receptor decreases cannot be attributed to degeneration of a specific population of cells, but rather appears to reflect downregulation of a specific subset of genes. These receptor changes, which occur at the levels of both protein and mRNA, precede and may therefore contribute to the onset of clinical symptoms. A transcription-related mechanism of huntingtin toxicity can also be inferred from other recent studies (5) (6) (7) . We therefore hypothesized that huntingtin-induced changes in gene expression might extend to functional categories besides neurotransmitter receptors and that understanding these changes might provide an insight into HD progression.
In the present study, we extended our previous analysis of gene expression in HD models to determine the scope of mRNAs affected by mutant huntingtin. Of nearly 6000 mRNAs that were measured, a small number were decreased, and these were remarkably restricted to genes encoding neurotransmitter, calcium and retinoid signaling pathway components. This study demonstrates that the decrease in the abundance of specific neurotransmitter receptors is associated with decreased expression of many genes that mediate the signaling response from these receptors. The data provide additional evidence that mutant huntingtin compromises the ability of striatal neurons to receive and integrate afferent input and establishes bases for rational therapeutic intervention.
RESULTS
We analyzed gene expression in the striata of R6/2 mice at both 6 and 12 weeks of age, representing stages of minimal and pronounced deterioration in neurological function, respectively (mice described in Materials and Methods). At each age, we extracted RNA from pooled striata of mice carrying the expanded exon 1 HD transgene and from wild-type littermate controls. Each RNA sample was divided in half and analyzed using two sets of Affymetrix murine expression arrays. Within each age group we made four comparisons: each data set from the HD transgenics to each of the two control data sets. Using the Affymetrix algorithm for assessing gene expression differences (8), we identified mRNAs that were increased or decreased in R6/2 mice relative to controls in all four comparisons (high stringency analysis). mRNAs that met this criterion are presented in Table 1A . We also analyzed the data by the criterion of three of four comparisons (moderate stringency analysis, Table 1B ). Because confirmation studies in our laboratory demonstrated that the Affymetrix algorithm-based change calls are reliable even when the fold change is relatively small, no arbitrary thresholds were imposed on the data set (see Confirmation of microarray findings below, Criteria for selecting affected genes in Materials and Methods and www.neumetrix.com ). Raw data and complementary data analyses (e.g. low stringency analysis and cross time point comparisons) are available at www.neumetrix.com . Using the three of four comparison cut-off, 1.7 and 1.2% of the genes tiled on the microarrays were changed in R6/2 mice compared with controls at 6 and 12 weeks, respectively. mRNAs that were decreased in R6/2 mice outnumbered those increased by 3:1. Increases were restricted largely to mRNAs associated with inflammatory and cell cycle function, while decreases were observed primarily in mRNAs involved in signal transduction, ion channels, transcription, metabolism and cell structure (Table 1 and Fig. 1 ). The representations of functional groups of molecules and the ratios between increased and decreased mRNAs obtained were similar using high, medium or low stringency criteria (Table 1 and www.neumetrix.com ).
It is important to note that the striatum represents a mixed population of neurons and glia and, therefore, the reported fold change might not accurately reflect the magnitude of change within an affected sub-population of cells. It is likely, however, that most of the neuron-specific gene changes are attributable to GABAergic medium spiny neurons, since these represent >85% of the neuronal population in striatum. The microarraybased results are presented in the next sections and are followed by northern blot and in situ hybridization histochemistry (ISHH) analyses that confirm and extend the data from the expression arrays.
Reduced expression of genes central to neural signaling
The most striking finding of this study was the relatively restricted decrease in mRNAs that encode neuronal signaling molecules (Table 1) . This study extends our previous observations that dopamine, glutamate and adenosine receptors are decreased in the R6/2 model of HD by demonstrating that multiple components of each of these signaling pathways are decreased at the mRNA level.
Neurotransmitter receptors, neurotransmitters and neuropeptides. Messenger RNAs encoding the G-protein-coupled receptors dopamine D 2 , dopamine D 4 , cannabinoid CB 1 , adrenergic α 2 and an orphan glucocorticoid-inducible receptor (GIR) were decreased in R6/2 mice. Expression of the suspected HD modifier gene GluR6 (29) was also decreased. mRNAs for some receptor interacting proteins were affected, including α-actinin 2 (which was decreased) and the heterotrimeric G-protein subunit Gγ 3 (which was increased). Decreases in mRNAs encoding the GABA-synthesizing enzyme glutamic acid decarboxylase and the neuropeptide precursors for enkephalin and somatostatin were also observed.
Signal transducing enzymes. Dysregulation of genes encoding signal transduction proteins in R6/2 mice extended beyond plasma membrane-bound receptors and involved many intracellular signaling components. These include adenylyl cyclases and phosphodiesterases, protein kinases and phosphatases, small G-proteins and inhibitors or regulatory subunits of these enzymes. These changes could affect synaptic transmission and plasticity, because the proteins in this category integrate, amplify and limit signals controlling many neuronal functions. In several instances, genes that encode proteins of opposing function are decreased. These balanced disruptions are consistent with the notion that expression of genes having opposing roles in signaling cascades is coordinately regulated. Even so, decreased expression of immediate early genes that are normally up-regulated by neuronal stimulation (Table 1) and reduced levels of adenylyl cyclase (see below) suggest that neuronal signal transduction is generally diminished.
Calcium homeostasis and mobilization. Calcium dysregulation has been postulated to be a component of HD pathology (30, 31) , but the mechanisms by which such changes occur have not been well defined. The present study revealed that this problem might be attributable, at least in part, to the downregulation of mRNAs whose products regulate calcium homeostasis and calcium signaling. Calcium-related mRNAs that showed decreased expression in the R6/2 striata include a plasma membrane calcium ATPase (PMCA1AB), the type 1 ryanodine receptor (RYR1), the type 1 inositol 1,4,5-trisphosphate receptor (IP 3 R1, P400), calcineurin, hippocalcin, a calmodulin-dependent phosphodiesterase (PDE1B1) and a calcium/calmodulin-dependent protein kinase (CAMK IV/Gr). In addition, many of the proteins in the signal transduction group are regulated or modulated by calcium and calciumsensing proteins. One possible mechanism by which mutant huntingtin may cause calcium signaling disturbances is through physical association with a calmodulin-containing complex (32) .
Nuclear hormone receptors. Retinoids (vitamin A derivatives) bind to nuclear hormone receptors and induce transcription of genes involved in neural differentiation and other processes (9) . Expression of the striatally enriched retinoic acid receptor, RXRγ, and a retinol-binding protein was decreased in R6/2 striata compared with controls. In addition, >20% of the genes less abundantly expressed in R6/2 striatum contain retinoic acid response elements and are induced by retinoic acid receptor agonists in cell culture experiments (Tables 1A and  1B) .
Unchanged expression of genes associated with neurodegenerative events or diabetes
Previous histopathological studies of R6/2 mice demonstrated that the striata of these animals show neither gross neuronal loss nor gliosis up to 13 weeks of age (33) . Consistent with these findings, no decreases in the expression of axonal or dendritic neuronal marker genes (e.g. MAP2 or neurofilaments) or increases in the expression of glial marker genes (e.g. glial fibrillary acidic protein, myelin basic protein or major histocompatability complex II components) were observed. Likewise, some mRNAs known to be expressed in medium spiny neurons (e.g. preprotachykinin) were unchanged. These findings indicate that decreases in the expression of neuronal signaling genes are not due to large shifts in striatal cell populations. While many components of signaling cascades implicated in human HD were obviously changed in R6/2 brains, some mechanisms previously associated with the disease were represented only minimally. For example, very few changes were detected in mRNAs that encode mitochondrial proteins, proteolytic enzymes or apoptotic molecules. This may be due to their regulation by post-transcriptional mechanisms. Alternatively, these HD-related toxicities may be modest, and thus undetectable, at the R6/2 time points selected. At 12 weeks, R6/2 animals are diabetic, showing both elevated baseline glucose levels and abnormal glucose tolerance tests, whereas 6-week-old animals handle glucose normally by these criteria (ref. 34 ; O. Andreasson and M.F. Beal, personal communication). Changes in mRNAs associated with glucose metabolism were not prominent in R6/2 mice at either age. Specifically, no differences in mRNAs, including glyceraldehyde phosphate dehydrogenase, glucose 6-phosphate isomerase, 6-phosphofructokinase, fructose bisphosphate aldolase, pyruvate dehydrogenase, phosphoglycerate kinase, lactate dehydrogenase and triose phosphate isomerase, were detected between R6/2 mice and controls. These data indicate that diabetes in R6/2 mice does not obscure the detection of bona fide huntingtin fragment-induced changes in gene expression. Within each outlined region, the top row of probes is comprised of oligonucleotides that are perfect sequence complements to the RNA of interest. The second row is comprised of control oligonucleotides, each of which differs from the perfectly matched probe tiled above it by a single base substitution. Difference calls are represented in the R6/2 panels by the following abbreviations: D, decrease in R6/2 relative to wild-type; I, increase in R6/2 relative to wild-type; NC, no change in R6/2 relative to wild-type. The pseudo-color hybridization scale is shown at the bottom of the figure.
Increased expression of genes associated with inflammation
Of over 6000 mRNAs represented on the microarrays, only 22 were increased in 6-week-old R6/2 mice and 21 were increased in 12-week-old mice compared with controls. In contrast to the mRNAs that were decreased in R6/2 mice, the increases in gene expression were generally not concentrated in discrete functional categories. The possible exceptions were mRNAs that encode stress or inflammation mediators and the expression of genes associated with cell cycle regulation. mRNAs increased at 6 weeks included rotamase/cyclophilin A and immunophilin P59. The proteins encoded by these mRNAs regulate the function of calcineurin, ryanodine receptors and phosphatidylinositol triphosphate (IP 3 ) receptors (see Calcium homeostasis and mobilization above) and are inhibited by immunosuppressants such as cyclosporin and FK506. At the 12-week time point cathepsin S, apolipoprotein D and MHC β2 microglobulin mRNAs were increased. These mRNAs are also induced in a mouse scrapie model, which represents another 'protein aggregation' disease (35) . Several inflammation-related mRNAs and other mRNAs that are increased in R6/2 mice were induced by interferon-α in mouse primary fibroblasts assayed on Mu6500 microarrays (Tables 1A and  1B ; S. Der and B. Williams, personal communication). Whether these mRNAs can be coordinately regulated in R6/2 mice by immune mediators remains to be determined.
Confirmation of microarray findings
In order to confirm changes in mRNA expression detected by the microarrays and to extend our understanding of the anatomical distribution of these changes, we performed northern blotting and in situ hybridization histochemistry (ISHH) experiments using independent litters of R6/2 mice. Northern hybridization results correspond to the array data for three decreased genes (zif268, GIR and PCTP), one unchanged gene (NMDA-NR1) and two increased genes (Gγ 3 and PA28α) in R6/2 mice (Fig. 2 ). mRNAs were also measured in brain tissue sections by ISHH (Fig. 3) . We confirmed striatal decreases for six mRNAs at 6 and 12 weeks and striatal increases in two mRNAs at 12 weeks by this method. These studies confirmed the array data with regard to differences in expression levels and provided anatomical resolution in the striatum and cortex. Cortical decreases in junB, N10 and zif268 at 6 and 12 weeks and cortical increases in Gγ 3 and PA28α at 12 weeks were observed.
Striatal gene expression profiles from 6-week-old R6/2 mice were directly compared with those from 12-week-old animals to determine whether there were changes indicative of disease progression (analysis not shown, refer to www.neumetrix.com ). While many genes in both R6/2 animals and controls differed between the two time points, certain mRNAs characteristic of mature medium spiny neurons, such as preproenkephalin, dopamine D 2 receptors and glutamic acid decarboxylase, decreased as neurological symptoms progressed. This was confirmed by the ISHH data for preproenkephalin and DARPP-32, another mRNA characteristic of this cell population (ref. 36 and Fig. 3 ). Previous ISHH assays have also shown progressive decreases in adenosine A 2a and dopamine D 1 and D 2 receptor mRNAs (3, 4) .
Type II and V adenylyl cyclases were decreased whereas type VII adenylyl cyclase was increased in the microarray analysis. To determine the overall impact on adenylyl cyclase levels, [ 3 H]forskolin binding assays were performed.
[ 3 H]forskolin binds to all adenylyl cyclase subtypes and provides a measure of adenylyl cyclase protein levels.
[ 3 H]forskolin binding was decreased in R6/2 striata to 24% of wild-type in 12-week-old animals (P = 0.0053, n = 5).
Signaling molecules affected in R6/2 mice are also decreased in other HD transgenic mice
The comparisons of R6/2 data to littermate controls demonstrated that the presence of the expanded repeat ITI5 exon 1 transgene resulted in the mRNA changes described above. To determine the extent to which these changes might be specific to this mouse model, we examined the expression of a subset of these mRNAs in another line of HD transgenic mice, N171-82Q (mice described in Materials and Methods and ref. 37 ). Significant decreases in symptomatic 4-month-old N171-82Q mice relative to N171-18Q or wild-type mice were observed in binding assays for dopamine D 2 receptors (78% control), adenosine A 2a receptors (61% control) and adenylyl cyclase (71% control) and in situ hybridization for D 2 (61% control), N10 (49% control), preproenkephalin (59% control) and DARPP-32 (62% control) ( Table 2) . ISHH for junB, Gγ 3 and zif268 was not different from controls (n = 3). Differences between the findings in R6/2 and N171-82Q lines could arise from differing polyglutamine lengths, promoters, transgene insertion sites or mouse strains. Overall, the concordance between microarray, northern, in situ and binding analyses performed on independent litters of mice from the two transgenic lines suggest that gene expression changes are characteristic of HD pathogenesis (see below). showing decreased expression in 6-and 12-week-old R6/2 mice [with percent controls calculated from mean optical densities (MODs) after subtraction of film background and sense cRNA MODs where applicable, unless otherwise indicated]: preproenkephalin (21% control striatum 12 weeks, 30% control striatum 6 weeks) zif268 (55% control striatum 12 weeks, 66% control cortex 12 weeks, 66% control striatum 6 weeks, 82% control cortex 6 weeks); junB (21% control striatum 12 weeks, 39% control cortex 12 weeks, 37% control striatum 6 weeks, 59% control cortex 6 weeks); N10 (50% control striatum 12 weeks, 58% control cortex 12 weeks, 50% control striatum 6 weeks, 72% control cortex 6 weeks); α-actinin 2 (70% control striatum 12 weeks, 72% control striatum 6 weeks); DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32 000) (33% control striatum 12 weeks, 54% control striatum 6 weeks). (B) Genes showing increased expression in 12-week-old R6/2 mice: PA28α (128% control striatum 12 weeks, 130% control cortex 12 weeks; percent control calculated from MOD film background); Gγ 3 (617% control striatum 12 weeks, 130% control cortex 12 weeks). (C) Genes showing unaltered expression in 6-and 12-week-old R6/2 mice: NMDA-NR1 (96% control striatum 12 weeks, 104% control striatum 6 weeks), β-actin (94% control striatum 12 weeks, 112% control cortex 12 weeks, 88% control striatum 6 weeks, 100% control cortex 6 weeks). Percentages of control and MODs represent the fraction of hybridization signals from four R6/2 and four wild-type animals.
Changes in gene expression in R6/2 brains parallel decreased mRNA and protein levels described in previous HD studies
It is important to consider whether the observed changes in steady-state mRNA populations in HD mouse models result in reduced protein levels and function and whether there is a link between mouse model data and human disease. In the present study, we addressed changes in protein levels in a limited fashion by demonstrating that forskolin binding was diminished in R6/2 mice and that binding to dopamine D 2 receptors, adenosine A 2a receptors and adenylyl cyclase was decreased in N171-18Q mice. Though extensive protein analysis was beyond the scope of this study, microarray-based mRNA findings were consistent with previous work that used both human tissue and mouse models of HD. Previous studies in our laboratory have shown decreases in A 2a , D 1 and D 2 receptor mRNAs and in corresponding protein levels based on receptor binding assays performed in three different lines of mice transgenic for a CAG-expanded exon 1 of the ITI5 gene (R6/1, R6/2 and R6/5) (3,4). In the HDex6 and HDex27 lines, which are transgenic for exon 1 of the human IT15 gene containing 18 CAG repeats, striatal levels of A 2a , D 1 and D 2 binding and mRNA are equivalent to wild-type animals, indicating that the CAG expansion of exon 1 is necessary for their down-regulation (4). In addition, other researchers have shown that decreases in preproenkephalin mRNA are associated with decreased enkephalin immunoreactivity in R6/2 striata (38) .
Parallels can also be found between decreased mRNAs in R6/2 striata and decreased mRNA and protein levels in human HD brains. Preproenkephalin mRNA is diminished in early stage human Huntington's disease brains (39, 40) . Human HD brains also show specific decreases in the enzymatic activities of neuron-specific enolase, protein kinase C isoform βII and glutamic acid decarboxylase (41) (42) (43) (2) . Although the subset of mRNAs in Table 1 that have been tested at the protein level is small, the results demonstrate that gene expression changes in the 6-and 12-week-old R6/2 striata mirror previously described changes in HD.
DISCUSSION
This study identified genes that were aberrantly expressed in the striata of R6/2 mice using an expression array that interrogates~6000 mRNAs. This screen, while far from saturating, identified gene networks that are affected by the HD mutation. Our data suggest that the dysregulation of mRNAs encoding neurotransmitter receptors and related second messenger systems is an early component of the pathological process. In addition, a small number of mRNAs responsive to inflammatory mediators were increased. mRNAs encoding mitochondrial proteins, caspases and other apoptosis-related molecules, all of which have been implicated in HD, were relatively unaffected. mRNAs encoding neuronal structural proteins were also generally unchanged between experimental and control mice, consistent with histopathological observations that R6/2 mice have normal cell counts (33) . Thus, RNA changes in these mice are not simply due to neuronal death.
Although we and others have previously demonstrated decreased expression of dopamine, glutamate and adenosine receptors in HD, this study demonstrates that many components of their signaling pathways and target genes are similarly reduced. In Figure 4 , genes whose expression is altered by mutant huntingtin are integrated into a schematic drawing of a striatal medium spiny neuron, demonstrating the extent to which signal transduction genes are affected. Reduced levels of neurotransmission-regulated immediate early gene mRNAs and adenylyl cyclase protein suggest that, overall, mutant huntingtin-mediated mRNA changes impair transduction of neuron-specific signals. Whether this is an adaptive response of neurons to mutant huntingtin remains to be determined. In addition to the decreased messages encoding afferent signaling molecules, decreased expression of preproenkephalin and glutamic acid decarboxylase suggests that medium spiny neurons may generate abnormally decreased efferent signals.
The array data further demonstrate abnormal expression of multiple genes involved in calcium signaling, consistent with studies in another mouse HD model that showed increased basal calcium levels and decreased glutamate-induced calcium mobilization (31) . The mRNA profiling in our study indicates that elevated basal calcium could be attributed to a diminution of plasma membrane calcium ATPase activity. Also, losses of mRNAs encoding IP 3 and ryanodine receptors, voltage-sensitive calcium channels, calcium-binding proteins, and calcium/ calmodulin-dependent enzymes could prevent the generation of appropriate calcium-mediated intracellular signals in response to glutamate. The blunting of calcium-mediated (Table 1A) or confirmed independently by another method (single asterisk). The color of each element represents the direction of the change; red elements are increased, blue elements are decreased and gray elements are either unchanged, did not meet the above criteria or have not been examined. Plain lines with triangular arrows represent sequential events or positive regulation; blunt bars represent negative regulation. Hatched arrows represent the flow of ions. Double asterisks indicate mRNAs detected as differentially expressed using medium stringency criteria. For the sake of presentation, only representative members of the protein phosphatase 1/DARPP-32 regulatory pathway are shown; a thorough review of this pathway can be found elsewhere (36) .
responses through all of these mechanisms could cause deficits in many important neuronal functions, including synaptic plasticity.
Both microarray and ISHH demonstrate that gene expression changes occur in minimally symptomatic animals and persisted during progression of the disease in R6/2 mice. This suggests that disease progression might represent the accumulation of neuronal damage caused by a persistent dysregulation of signaling systems. It has been shown that long-term potentiation (LTP) and long-term depression (LTD) deficits occur in transgenic models of HD, including R6/2 mice (ref. 31 This study also provides the first evidence that impaired retinoid signaling might contribute to HD pathophysiology. In addition to decreased RXRγ, retinoic acid signaling regulates at least 22 of the 104 genes that show decreased expression in R6/2 mice. The disruption of RA signaling by mutant huntingtin can be explained by either of two mechanisms: first, dopamine can positively regulate the expression of retinoic acid receptor genes and the diminished activity of the dopamine signaling pathway in HD might decrease RXRγ expression (10); second, the nuclear co-repressor NCoR binds both mutant huntingtin and retinoic acid receptors (7, 11) and could sequester receptors in a non-functional complex. It is interesting to note that glial cells in the lateral striatum produce more retinoids than those in the medial striatum, resulting in a concentration gradient across the structure that is opposite to the gradient of neural degeneration in HD (12) . In other words, the striatal neurons that degenerate first in HD are those surrounded by the lowest concentration of retinoids.
The signaling pathways affected by the mutant huntingtin protein represent logical targets for therapeutic intervention. The current data indicate a potential therapeutic role for drugs that restore neuronal calcium homeostasis, modulate dopamine or glutamate signaling pathways or that inhibit inflammatory responses. Because retinoic acid analogs have been clinically demonstrated to overcome retinoic acid receptor deficits (e.g. in acute promyelocytic leukemia; ref. 48) , it is possible that the deficits in HD striatal neuron retinoic acid receptors and binding proteins could be compensated for by pharmacological doses of retinoic acid agonists. The identification of a distinct gene expression signature in the striata of R6/2 mice provides a valuable reference for the rapid assessment of therapeutic efficacy in candidate drug screens.
MATERIALS AND METHODS

Animals
Female R6/2 mice (33) and wild-type controls (F1) were purchased from The Jackson Laboratory (Bar Harbor, ME) and killed at 5-6 or 11-12 weeks of age. R6/2 mice express exon 1 of the human IT15 gene containing an extremely expanded CAG repeat (140-147) under control of the human IT15 promoter. These animals appear to develop normally through weaning, but display subtle deficits starting at 5-6 weeks of age which progress to a resting tremor, involuntary movements, stereotypic grooming and handling-induced seizures by 9-12 weeks of age (33, 49) .
N171-82Q mice and controls (N171-18Q and wild-type) (37) were obtained from the authors' colony (G.S., C.A.R. and D.R.B.) and killed at 4 months of age (late symptomatic stage for the N171-82Q mice). The N171 mice used for the present study carry a transgene encoding the N-terminal 171 amino acids of human huntingtin with a polyglutamine repeat length of 18 (N171-18Q) or 82 (N171-82Q), expressed under the control of the PrP promoter. Phenotypically, N171-82Q animals show loss of coordination, tremors, hypokinesis, gait abnormalities and premature death (37) .
Gene expression changes in R6/2 and N171-82Q mice are attributable to an N-terminal portion of the human huntingtin protein expressed from a partial IT15 transgene. There are several lines of evidence to support the relevance of a similar mutant huntingtin fragment to the human disease. First, a similar proteolytic fragment of huntingtin has been detected in human HD brains and those of several HD models (32, 50) . Second, such a fragment has a higher propensity for aggregation (50,51) and appears to be present in huntingtin-positive aggregates in human brain (52) . Additionally, this fragment contains structural domains that mediate most of huntingtin's known protein-protein interactions (7, 53, 54) .
Tissue
For RNA extractions, the striata were dissected bilaterally, removed immediately to dry ice and stored at -70°C until the tissue was processed. For in situ hybridization histochemistry and autoradiographic studies, brains were frozen whole by immersion in isopentane on dry ice for 3 min, then stored at -70°C until the tissue was sectioned. Cryostat sections (12 µm) containing striatum and cortex were thaw mounted onto polylysine-coated glass slides.
RNA extraction
RNA was extracted using TRI-Reagent (Sigma, St Louis, MO) according to the manufacturer's recommended protocol, except that the isopropanol precipitation step was performed at -20°C overnight. RNA pellets were resuspended in nucleasefree water and quantitated spectrophotometrically.
Preparation of labeled cRNA
RNA from the striata of six R6/2 or six age-matched wild-type animals at each age was combined to comprise each sample, consisting of 70-100 µg of total RNA. Poly(A) + RNA was isolated from the samples using Oligotex mRNA isolation kits (Qiagen, Chatsworth, CA). At this point the samples were split in half and all further procedures were performed on each pool independently. Biotinylated cRNAs were prepared per Affymetrix protocol. Labeled cRNA (32 µg) was fragmented in 40 µl of 40 mM Tris-acetate pH 8.0, 100 mM KOAc, 30 mM MgOAc for 35 min at 95°C. The fragmented cRNA was brought to a final volume of 300 µl in hybridization buffer containing 100 mM MES, 20 mM EDTA, 0.01% Tween-20 (all from Sigma), 1 M NaCl (Ambion, Austin, TX), 0.5 mg/ml acetylated BSA (Gibco BRL, Gaithersburg, MD), 0.1 mg/ml herring sperm DNA (Promega, Madison, WI) and biotinylated controls B2, BioB, BioC, BioD and Cre (Affymetrix, Santa Clara, CA) at 50, 1.5, 5, 25, 100 pM, respectively.
Array hybridization
Mu6500 A, B, C and D oligonucleotide arrays were prehybridized, hybridized, washed and stained as recommended by the manufacturer (Affymetrix) using a GeneChip Fluidics Station 400 (Affymetrix). The arrays were hybridized sequentially over the course of 4 days using 200 µl of cRNA (0.1 µg/µl) per hybridization. After hybridization of one array, the aliquot was recovered from the array, recombined with the unused portion of the sample and frozen. This process was repeated with each sample until the sample had been hybridized to the entire set of four arrays. Immediately after washing and staining, the probed arrays were scanned with a Hewlett Packard GeneArray scanner. The scanned images were analyzed and compared using GeneChip3.1 software (Affymetrix) (8) . Images were globally scaled to compensate for minor variations in fluorescence and bring the mean average difference for all of the genes on each array to 2500 intensity units.
Criteria for selecting affected genes
We designed our study to minimize potential experimental confounds as follows. First, we used a pooled sample for the Affymetrix GeneChip analysis, followed by validation in independent litters of mice in order to minimize effects of animalto-animal and litter-to-litter variability. Second, we analyzed each sample in duplicate, to control for differences in efficiency of mRNA amplification and chip variability. Third, we confirmed a subset of our findings by other methodologies and in other lines of HD transgenic mice.
We compared each R6/2 sample to both age-matched control samples, thus for each age of mice obtaining four mutant to wildtype comparisons. We used the default parameters in the GeneChip3.1 software to call mRNAs increased, decreased or not changed in the R6/2 striata relative to the controls. No additional thresholds (e.g. minimum fold change) were introduced. The GeneChip3.1 Difference Call Decision Matrix (8) is a metric based on the magnitude and sign of the hybridization signal difference between the two samples being compared plus a tallying of the various oligonucleotide probes that have a positive or negative signal change. Typically, the genes on the arrays are represented by an average of 20 probe pairs. mRNAs that were called as increased or decreased in at least three of the four comparisons were designated for inclusion in this report. This cut-off was chosen based on the following considerations: (i) prior findings show a >90% concordance between Affymetrix microarray data and northern/S1 protection assay data in studies of similar design (J.M. Olson, A. Strand and S.J. Tapscott, unpublished observations); (ii) comparison of two hybridizations of the same sample yields a call rate <1% (which can be considered an estimate of the 'false positive' rate). Thus, the representation of mRNAs called in three of four comparisons at a false positive rate of up to 1% is extremely low. Table 1 lists genes that differed between R6/2 and wild-type striata in 4/4 (high stringency) and 3/4 (moderate stringency) comparisons and the entire data set is available at www.neumetrix.com . As mentioned above, the persistent expression of genes in cells not affected by mutant huntingtin serves to reduce the apparent magnitude of any changes. A less stringent examination of the data that relies solely on the probe pairs is also presented at www.neumetrix.com
Probes for in situ and northern hybridization
Probe sequences used for in situ and northern hybridization were cloned by RT-PCR, obtained as I.M.A.G.E. Consortium clones (from Genome Systems, St Louis, MO) or ordered as custom oligonucleotides (from Gibco BRL). Oligonucleotide primers and probes were either designed (those listing GenBank accession nos) using Oligo 4.06 software (National Biosciences, Plymouth, MN) and analyzed for specificity by database searching using BLASTN (National Center for Biotechnology Information, Bethesda, MD) or selected based on use in previous studies. T7 and SP6 promoter sequences (CTGTAATACGACTCACTATAGGG and GGGATTTAG-GTGACACTATAGAA, respectively) were added to the 5′-ends of PCR primers in some cases for use in in vitro transcription of riboprobes. Gene-specific sequences of primers used to clone probes by RT-PCR were as follows: α-actinin 2 (GenBank accession no. AA800206), CGTAGAGGGCAGGA-GAAG and TTTGACAGGAGGAAGAATGG; NMDA-NR1, GGAGTGGAACGGAATGATGG and AAAGCCTGAGCG-GAAGAACA (outer) and CTGTAATACGACTCACTATAG-GGTTATGCAGCCTTTTCAGAGC and GGGATTTAGGTG-ACACTATAGAAGCACGGCCGAGTCCCAGAT (inner); zif268 (GenBank accession no. M22326), GTTCGGCTCCTT-TCCTCACT and GCCTCTTGCGTTCATCACTC (outer) and TGAAGAAGGCGATGGTGGAGA and GGCAGAGGAA-GACGATGAA (inner). PCR-generated probe templates were purified using a Strataprep PCR Purification Kit (Stratagene, La Jolla, CA). The following in situ probes were obtained as I.M.A.G.E. Consortium clones: GIR (ID 421187); Gγ 3 (ID 47893); PA28α (ID 598746). Oligonucleotide in situ probes comprised: DARPP-32 (GenBank accession no. U23160), GAGCTGGCTCGGGGGCGCGGGCACAGAGAA; junB, ACTGGGCGCAGGCGGGCGGGCCGGAGTCCAGTGTGT-GAGCTGCGCC; N10, GTGGTCACGCGGTCCTGGGCTC-GTTGCTGGTGTTCCATATTGAGC; β-actin, GCCGATCC-ACACGGAGTACTTGCGCTCAGGAGGAGCAAT-GATCTT; preproenkephalin (GenBank accession no. M28263), ATCTGCATCCTTCTTCATGAAACCGCCATACCTCTT-GGCAAG GATCTC. Probes used for the following northern blots were generated by PCR subcloning partial I.M.A.G.E. Consortium clone sequences: PA28α (primers AGAAGAAAG-GGGACGAAGAC and TGTTTGGGAGGCAGAGTGAG); Gγ 3 (primers CTCCCCACTGACCCTACATC and CTGCCTT-GGACACCTTTATC); GIR (primers TGACAGCTATCG-CAGTGGAC and CAGCAGAGGGCAAAGAGGAC). The identities of PCR products and I.M.A.G.E. Consortium clones were confirmed by sequencing.
Northern analysis
Two micrograms of each RNA sample were denatured in 1× MOPS containing 50% formamide and 3% formaldehyde, electrophoresed through a 1.2% agarose gel containing 3% formaldehyde and electorphoretically transferred to a nylon membrane. Random primed 32 P-radiolabeled cDNA probes (sp. act.~6.0 × 10 9 d.p.m./µg) were prepared using a Prime-It kit (Stratagene). Oligonucleotide probes were labeled using the Renaissance oligonucleotide 3′-end-labeling system (NEN Life Sciences). Hybridization took place overnight at 42°C, and final high-stringency washes were performed with 0.5× SSC (for oligonucleotide probes) or 0.1× SSC (for cDNA probes) plus 0.1% SDS at 42°C. Hybridization was detected by autoradiography using a Molecular Dynamics PhosphorImager (Sunnyvale, CA) and the signal was quantitated using ImageQuant software (v.1.2).
In situ hybridization histochemistry
PCR products and I.M.A.G.E. clones (above) were used as templates for in vitro transcription of 35 S-labeled riboprobes. Oligonucleotide probes were prepared using the Renaissance oligonucleotide 3′-end-labeling system and purified with NENsorb columns (NEN Life Sciences). ISHH was conducted according to Landwehrmeyer et 
Receptor and adenylyl cyclase autoradiography
All studies were performed on coded samples by experimenters blinded to the genotype status of the animals. Dopamine D 1 and D 2 receptor assays used a buffer containing 25 mM TrisHCl pH 7.5, 100 mM NaCl, 1 mM MgCl 2 , 1 µM pargyline and 0.001% ascorbate. For D 1 receptors, slides were incubated with 1.65 nM [ 3 H]SCH-23390 (sp. act. 70.3 Ci/mmol; NEN Life Sciences) for 2.5 h. Non-specific binding was defined in the presence of 1 µM cis-flupentixol (57) . For D 2 receptors, slides were incubated with 180 pM [ 3 H]YM-09151-2 (sp. act. 85.5 Ci/mmol) for 3 h. Non-specific binding was defined in the presence of 50 µM dopamine (58) . For adenosine A 2a receptors, the buffer used was 50 mM Tris-HCl, pH 7.4 with 10 mM MgCl 2 . Following a preincubation for 30 min at room temperature in buffer containing 2 IU/ml adenosine deaminase, slides were incubated in buffer containing 5 nM [ 3 H]CGS 21680 (sp. act. 39.5 Ci/mmol) for 90 min (59) . Non-specific binding was defined in the presence of 20 µM 2-chloroadenosine. Slides were rinsed for 5 min in ice-cold buffer, then quickly in ice-cold ddH 2 O and dried rapidly under a stream of warm air. For adenylyl cyclase, slides were incubated in 10 nM [ 3 H]forskolin in 50 mM Tris-HCl with 100 mM NaCl and 5 mM MgCl 2 for 10 min at room temperature (60) . Slides were rinsed twice for 2 min at 4°C and then dried. Slides were apposed to tritium-sensitive film (Hyperfilm 3 H; Amersham) with calibrated radioactive standards and exposed for 1-3 weeks. Films were developed and analyzed using a computerbased image analysis system (M1; Imaging Research). Image density corresponding to binding of [ 3 H]ligand was converted to pmol/mg protein using calibrated radioactive standards and non-specific binding was subtracted.
